Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy without a price target While the headline overall response rate in the silevertinib 1L non-classical EGFRm phase 2 trial is “competitive,” there was very high toxicity and there are questions around potential durability, the analyst tells investors in a research note. The firm sees risk to the 2Q26 progression free survival catalyst and Phase 3 start up execution.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
- Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated
- Black Diamond Reports Promising Phase 2 Lung Cancer Data
- Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
- Black Diamond Therapeutics assumed with an Overweight at Piper Sandler